Research programme: selective nicotinic acetylcholine receptor antagonists - Suven Life Sciences

Drug Profile

Research programme: selective nicotinic acetylcholine receptor antagonists - Suven Life Sciences

Alternative Names: SUVN-911

Latest Information Update: 24 Oct 2016

Price : $50

At a glance

  • Originator Suven Life Sciences
  • Class
  • Mechanism of Action Alpha4beta2 nicotinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Major depressive disorder

Highest Development Phases

  • Preclinical Major depressive disorder; Pain

Most Recent Events

  • 18 Oct 2016 Suven Life Sciences has patent protection for selective alpha-4-beta-2 receptor and H3 Inverse agonists for the treatment of major depressive disorder in Europe and Israel
  • 29 Jun 2016 Suven Life Sciences has patent protection for selective alpha-4-beta-2 receptor antagonists in Eurasia
  • 29 Dec 2015 Suven Life Sciences has patent protection for alpha-4-beta-2 compounds for the treatment of major depressive disorder in Europe and Macau
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top